Business Segments · SG&A
Reportable Segment — SG&A
Biogen Reportable Segment — SG&A remained flat by 0.0% to $608.40M in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 1.2%, from $600.93M to $608.40M. Over 3 years (FY 2022 to FY 2025), Reportable Segment — SG&A shows relatively stable performance with a 0.4% CAGR. This is a positive signal — lower values indicate better performance for this metric.
Analysis
StatementSegment
CategoryEfficiency
SignalLower is better
VolatilityStable
First reportedQ1 2022
Last reportedQ4 2025
Rolls up toSG&A
How to read this metric
A decrease relative to revenue suggests improved operational leverage, while an increase may signal higher marketing investment or rising overhead.
Detailed definition
This encompasses the costs of marketing, sales force operations, legal, and general corporate overhead required to suppo...
Peer comparison
Standard 'SG&A Expense' reported across all industries.
Metric ID:
biib_segment_reportable_segment_selling_general_and_administrativeHistorical Data
4 years
| FY'22 | FY'23 | FY'24 | FY'25 | |
|---|---|---|---|---|
| Value | $2.40B | $2.55B | $2.40B | $2.43B |
| YoY Change | — | +6.1% | -5.7% | +1.2% |
Range$2.40B – $2.55B
CAGR+0.4%
Avg YoY Growth+0.5%
Median YoY Growth+1.2%
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Biogen's reportable segment — sg&a?
- Biogen (BIIB) reported reportable segment — sg&a of $608.40M in Q4 2025.
- How has Biogen's reportable segment — sg&a changed year-over-year?
- Biogen's reportable segment — sg&a increased by 1.2% year-over-year, from $600.93M to $608.40M.
- What is the long-term trend for Biogen's reportable segment — sg&a?
- Over 3 years (2022 to 2025), Biogen's reportable segment — sg&a has grown at a 0.4% compound annual growth rate (CAGR), from $2.40B to $2.43B.
- What does reportable segment — sg&a mean?
- The total costs of marketing, sales, and general administrative support for the business segment.